[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
SourceEuropean Journal of Nuclear Medicine and Molecular Imaging, 49, 13, (2022), pp. 4736-4747
Article / Letter to editor
Display more detailsDisplay less details
European Journal of Nuclear Medicine and Molecular Imaging
SubjectRadboudumc 14: Tumours of the digestive tract RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 19: Nanomedicine RIMLS: Radboud Institute for Molecular Life Sciences
PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted PET/CT has become increasingly important in the management of prostate cancer, especially in localization of biochemical recurrence (BCR). PSMA-targeted PET/CT imaging with long-lived radionuclides as <sup>89</sup>Zr (T<sub>1/2</sub> = 78.4 h) may improve diagnostics by allowing data acquisition on later time points. In this study, we present our first clinical experience including preliminary biodistribution and dosimetry data of [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in patients with BCR of prostate cancer. METHODS: Seven patients with BCR of prostate cancer who revealed no (n = 4) or undetermined (n = 3) findings on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT imaging were referred to [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT. PET/CT imaging was performed 1 h, 24 h, 48 h, and 72 h post injection (p.i.) of 111 +/- 11 MBq [<sup>89</sup>Zr]Zr-PSMA-617 (mean +/- standard deviation). Normal organ distribution and dosimetry were determined. Lesions visually considered as suggestive of prostate cancer were quantitatively analyzed. RESULTS: Intense physiological uptake was observed in the salivary and lacrimal glands, liver, spleen, kidneys, intestine and urinary tract. The parotid gland received the highest absorbed dose (0.601 +/- 0.185 mGy/MBq), followed by the kidneys (0.517 +/- 0.125 mGy/MBq). The estimated overall effective dose for the administration of 111 MBq was 10.1 mSv (0.0913 +/- 0.0118 mSv/MBq). In 6 patients, and in particular in 3 of 4 patients with negative [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT, at least one prostate cancer lesion was detected in [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT imaging at later time points. The majority of tumor lesions were first visible at 24 h p.i. with continuously increasing tumor-to-background ratio over time. All tumor lesions were detectable at 48 h and 72 h p.i. CONCLUSION: [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT imaging is a promising new diagnostic tool with acceptable radiation exposure for patients with prostate cancer especially when [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT imaging fails detecting recurrent disease. The long half-life of <sup>89</sup>Zr enables late time point imaging (up to 72 h in our study) with increased tracer uptake in tumor lesions and higher tumor-to-background ratios allowing identification of lesions non-visible on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT imaging.
This item appears in the following Collection(s)
- Academic publications 
- Faculty of Medical Sciences 
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.